Due Diligence

A comprehensive appraisal of assets and liabilities undertaken by DelveInsight to provide a bright outlook of an asset or a business or an entity.
Request for proposal
Misrepresentation is a very frequent problem Pharma industry has to go through while conducting M&A, Collaboration, or Partnership deals and while conducting C-level hiring. Not obtaining necessary information before time can cause mistakes in properly valuing deals, leading to problematic business operation in the future

Our Perspective

Working through the quagmire of uncertainties is DelveInsight, whose team is well-equipped to gather intelligent data relating to a business, an entity or an individual, conduct activities that authenticate claims and provide insight on the suitability of the proposition. Through DelveInsight’s detailed analysis, our clients can be assured of the authenticity of a claim, correct representation of facts, and the possible ramifications of entering into a deal.
Our Due Diligence Service helps by:

Insights

Due Diligence study

Due Diligence

A medium pharmaceutical client with capabilities in novel formulations was involved in a deal with a manufacturing company for commercial-scale manufacturing of the client’s therapies. [...]

Pipeline Assessment study

Pipeline Assessment

A medium pharmaceutical client based in the United States with capabilities in cancer immunotherapy domain involved DelveInsight to analyze current pipeline activity of T-Cell Receptor (TCR) products for cancer treatment. [...]

Launch landscape analysis study

Launch Landscape Analysis

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing [...]

Out-licensing opportunity study

Out-Licensing Opportunity

A Small Pharmaceutical Client Based At Sweden, Europe With Capabilities Around A Neonatal Mesenchymal Cells Involved DelveInsight [...]

Request For Proposal

*I consent to DelveInsight gathering details provided via this form. Check our Privacy Policy to know more.